The Skin Cancer Foundation Journal

MAY 2015

The 2012 edition of The Skin Cancer Foundation Journal features medically reviewed, reader-friendly articles such as tanning, the increasing incidence of skin cancer diagnoses among young women, & the prevalence of melanoma among white males over 50.

Issue link: https://skincancer.epubxp.com/i/526209

Contents of this Issue

Navigation

Page 107 of 115

1 0 6 For the latest information and updates go to: SkinCancer.org References, Continued CHUCK DEVOE AND A LIFE WELL-LIVED (P.60) 1. Skin Types and At-Risk Groups. skincancer.org/ prevention/are-you-at-risk/skin-types-and-at-risk-groups. Accessed March 26, 2015. 2. Parkin DM, Mesher D, Sasieni P. Cancers attribut- able to solar (ultraviolet) radiation exposure in the UK in 2010. Br J Cancer 2011; 105:S66-S69. KNOW YOUR ABCDES (P.63) 1. American Cancer Society. Cancer Facts & Figures 2015. http://www.cancer.org/acs/groups/content/@editorial/ documents/document/acspc-044552.pdf. Accessed January 9, 2015. ASHLEY'S JOURNEY (P.64) 1. Harrington CR, Beswick TC, Graves M, et al. Activa- tion of the mesostriatal reward pathway with exposure to ultraviolet radiation (UVR) vs. sham UVR in fre- quent tanners: a pilot study. Addict Biol 2012 May; 17(3):680-6. 2. American Cancer Society. Cancer Facts & Figures 2015.http://www.cancer.org/acs/groups/content/@ editorial/documents/document/acspc-044552.pdf. Accessed January 9, 2015. VITAMIN D: A BAD EXCUSE FOR A TAN (P.68) 1. Woo DK, Eide MJ. Tanning beds, skin cancer, and vitamin D: an examination of the scientifc evidence and public health implications. Dermatol Ther 2010; 23:61-71. 2. Levine JA, Sorace M, Spencer J, Siegel DM. The in- door UV tanning industry: a review of cancer risk, health beneft claims and regulation. J Am Acad Dermatol 2005; 53:1038-44. 3. Demierre MF. Time for the national legislation of indoor tanning to protect minors. Arch Dermatol 2003; 139:520-4. 4. Gilchrest BA. Sun protection and vitamin D: three dimensions of obfuscation. J Steroid Biochem Mol Biol 2007; 103:655-63. 5. Wolpowitz D, Gilchrest BA. The vitamin D questions: how much do you need and how should you get it? J Am Acad Dermatol 2006; 54:301-17. 6. MacLaughlin JA, Anderson RR, Holick FF. Spectral character of sunlight modulates photosynthesis of pre- vitamin D3 and its photoisomers in human skin. Science 1980; 216:1001-3. 7. Eller MS, Ostrom K, Gilchrest BA. DNA damage enhances melanogenesis. Proc Natl Acad Sci 1996; 93:1087-1092. 8. Koh HK, Geller AC, Miller DR, Grossbart TA, Lew RA. Prevention and early detection strategies for mela- noma and skin cancer: Current status. Arch Derm 1996; 132:436-442. 9. Parkin DM, Mesher D, Sasieni P. Cancers attribut- able to solar (ultraviolet) radiation exposure in the UK in 2010. Br J Cancer 2011; 105:S66-S69. 10. National Toxicology Program. Report on Carcino- gens, Twelfth Edition. U.S. Department of Health and Human Services, Public Health Service, National Toxicol- ogy Program. 2011: 429-430. http://ntp.niehs.nih.gov/ ntp/roc/twelfth/profles/UltravioletRadiationRelatedEx- posures.pdf. Accessed February 12, 2012. 11. Wehner M, Chren M-M, Nameth D, et al. Interna- tional prevalence of indoor tanning: a systematic review and meta-analysis. JAMA Dermatol 2014; 150(4):390- 400. Doi: 10.1001/jamadermatol.2013.6896. 12. El Ghissassi F, Baan R, Straif K, et al. Special report: policy. A review of human carcinogens—part D: radia- tion. The Lancet 2009; 10(8):751-752. 13. Ogden N. General and Plastic Surgery Devices: Re- classifcation of Ultraviolet Lamps for Tanning, Henceforth To Be Known as Sunlamp Products and Ultraviolet Lamps Intended for Use in Sunlamp Products. https://www. federalregister.gov/articles/2014/06/02/2014-12546/ general-and-plastic-surgery-devices-reclassifcation-of- ultraviolet-lamps-for-tanning-henceforth-to. Accessed June 9, 2014. 14. Ernst A, Grimm A, Lim HW. Tanning lamps: health effects and reclassifcation by the Food and Drug Admin- istration. J Am Acad Dermatol 2015; 72:175-80. 15. National Academies, Institute of Medicine, Food and Nutrition Board. Dietary reference intake for calcium and vitamin D. http://www.iom.edu/Reports/2010/ Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D. aspx . Nov. 30, 2010. Accessed Feb. 2, 2012. 16. Haines ST, Park SK. Vitamin D supplementation: what's known, what to do, and what's needed. Pharma- cother 2012; 32:354-82. 17. Chameides B. Update: our rickety understanding of vitamin D. Duke University, Nichols School of the Environment. The Green Grok. http://www.nicholas. duke.edu/thegreengrok/vitamind-report. Dec. 7, 2010. Accessed Feb. 1, 2012. 18. The Nutrition Source. Vitamin D and health. Harvard School of Public Health. http://www.hsph.harvard.edu/ nutritionsource/what-should-you-eat/vitamin-d/#iom- vitamin-d. March 29, 2011. Accessed Feb. 2, 2012. HOW MUCH VITAMIN D DO YOU NEED? (P.71) 1. Vitamin D—Health Professional Fact Sheet. National Institutes of Health Offce of Dietary Supplements. http://ods.od.nih.gov/factsheets/VitaminD-Health Professional/. Checked April 7, 2015. 2. National Academies, Institute of Medicine, Food and Nutrition Board. Dietary reference intake for calcium and vitamin D. http://www.iom.edu/Reports/2010/ Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D. aspx. Nov. 30, 2010. Accessed Feb. 2, 2012. 3. The Nutrition Source. Vitamin D and health. Harvard School of Public Health. http://www.hsph.harvard.edu/ nutritionsource/what-should-you-eat/vitamin-d/#iom- vitamin-d. March 29, 2011. Accessed Feb. 2, 2012. REMEMBER TO ALWAYS EAT YOUR D'S (P.71) 1. Vitamin D—Health Professional Fact Sheet. National Institutes of Health Offce of Dietary Supplements. http://ods.od.nih.gov/factsheets/VitaminD-Health Professional/ . Checked April 7, 2015. A SUN DAY IN THE LIFE OF YOUR CHILD (P.72) 1. Wu S, Han J, Laden F, Qureshi AA. Long-term ultra- violet fux, other potential risk factors, and skin cancer risk: a cohort study. Cancer Epidemiol Biomar Prev 2014; 23(6):1080-1089. 2. Sun Screen. The burning facts. United States Environ- mental Protection Agency. http://www.epa.gov/sunwise/ doc/sunscreen.pdf 3. Implications of the blue light hazard and (ROS) in the pathogenesis of age-related macular degeneration, Dr. George Banyas, OD. Midwest Labs white paper. 4. HEV Light and Macular Degeneration, Midwest Monthly, Vol. 5, Issue 3, March 2008. http://mwlabs.cc/ pdf/MMMarch2008.pdf. 5. National Eye Institute, National Institutes of Health, Age-Related Macular Degeneration, www.nei.nih.gov/ health/maculardegen/armd_facts.asp 6. Mac-Mary S, Sainthillier J-M, Jeudy A, et al. Assess- ment of cumulative exposure to UVA through the study of asymmetrical facial skin aging. Clinical Interventions in Aging 2010; 5:277-284. 7. Texas mom burning mad over school's sunscreen ban. Fox News, June 8, 2014. http://www.foxnews.com/ us/2014/06/08/texas-mom-burning-mad-over-schools- sunscreen-ban/ 8. Ong E, Goldacre R, Sinclair R. Risk of subsequent malignant melanoma in patients with melanocytic nae- vus in England: a national record-linkage study. Paper presented at World Congress on Cancers of the Skin; 2014; Edinburgh, Scotland. 9. MedicineNet.com. Freckles. http://www.medicine net.com/freckles/article.htm. Viewed March 24, 2015 . THE IMMUNE REVOLUTION (P.76) 1. American Cancer Society. Cancer Facts & Figures 2015. http://www.cancer.org/acs/groups/content/@editorial/ documents/document/acspc-044552.pdf. Accessed January 9, 2015. 2. Schadendorf D, Hodi FS, Robert C. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma (abstract 24), Melanoma and Skin Cancer, European Cancer Congress 2013. http:// eccamsterdam2013ecco-org.eu/Scientifc-Programme/ Abstract-search.aspx#. Last checked February 13, 2014. 3. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26):2443-54. 4. Wolchok JD, Kluger H, Callahan MK, et al. Nivolum- ab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369(2):122-33. 5. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with du- rable clinical beneft in melanoma patients. Clin Cancer Res 2013; 19(19):5300-9. 6. Berberabe T. PD-1 agents vie for frontline spot in melanoma immunotherapy. OncLive Friday, February 27, 2015. http://www.onclive.com/web-exclusives/ PD-1-Agents-Vie-for-Frontline-Spot-in-Melanoma- Immunotherapy . References S K I N C A N C E R F O U N D A T I O N

Articles in this issue

Links on this page

Archives of this issue

view archives of The Skin Cancer Foundation Journal - MAY 2015